NEW YORK (GenomeWeb) – OvaGene and Indian life sciences firm iLife Discoveries today announced an alliance to bring gene-based assays targeting ovarian, endometrial, and cervical cancer to India.

Initially, the partners will validate and commercialize novel assays that clinicians can use to evaluate therapeutic alternatives. Eventually, they also plan to offer expanded diagnostic and predictive services, Irvine, Calif.-based OvaGene said.

Financial and other terms of the agreement were not disclosed.

In a statement, OvaGene Chairman and CEO Frank Kiesner said the deal provides his firm access to iLife’s network of 1,200 sales people in India, and the Indian subcontinent, including Sri Lanka, Bangladesh, Pakistan, and Nepal, and “will bring advanced molecular innovation to the bedside of gynecologic cancer patients within these populous markets.”

On Thursday, OvaGene announced an R&D collaboration with Hitachi Chemical Research Center to develop mRNA-based signatures for gynecologic cancers.